Stock news
11 stories match “FUL”
Market narrative auditsWhat Must Palantir Technologies Inc. (NASDAQ: PLTR) Prove in Q3?The Q3 revenue midpoint requires 11.7% sequential growth. Hitting the full-year midpoint would still leave another 12.1% revenue step-up for Q4. PLTR · OptimistFi Research Desk ·
Investor guidesWhy Is Palantir Technologies Inc. (NASDAQ: PLTR) Stock Up 17% This Year?Revenue growth accelerated from 85% in the first quarter to 93% in the second, but the October 13 close still implied roughly 62 times the latest full-year revenue guide. PLTR · OptimistFi Research Desk ·
Market narrative auditsBroadcom Inc. (NASDAQ: AVGO) Has a $42 Billion Anthropic TestThe conditional note facility was unused on Aug. 2, while a separate lease backstop could reach about $29 billion after full deployment. AVGO · OptimistFi Research Desk ·
Market narrative auditsBiotech2k Tests Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)'s FOP UpsideBiotech2k says Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)'s Atebrioz is medically useful but financially modest. The patient pool, licensing costs and an existing rival explain why. MIRM · OptimistFi Research Desk ·
Market narrative auditsH.B. Fuller Company (NYSE: FUL) Raised Prices as Volume FellAdjusted gross margin rose 120 basis points to 33.5%, but pricing more than accounted for organic growth. FUL · OptimistFi Research Desk ·
Investment case changesScholastic Corporation (NASDAQ: SCHL) Needs a $148 Million Cash ReboundFirst-quarter cash use widened, leaving Scholastic $148.3 million of positive free cash flow to reach its full-year midpoint. SCHL · OptimistFi Research Desk ·
Market narrative auditsAsif Suria Tests D.R. Horton, Inc. (NYSE: DHI) Buyback SignalSuria's useful distinction is that a company buyback does not equal insiders buying with personal money. SEC records support his observation, while the new capacity equals 12.8% of current market value. DHI · OptimistFi Research Desk ·
Market narrative auditsPulse Biosciences, Inc. (NASDAQ: PLSE) Lines Up Cash for Its Next Clinical TestsAn $85 million share-sale program could fund development as a thyroid study reaches full enrollment. Shareholders need to weigh that progress against dilution. PLSE · OptimistFi Research Desk ·
Investment case changesSummit Therapeutics Inc. (NASDAQ: SMMT) Adds Detail to Lung-Cancer Survival DataSummit Therapeutics Inc. (NASDAQ: SMMT) reported fuller ivonescimab survival results. The global finding improved, but Western data remain inconclusive. SMMT · OptimistFi Research Desk ·
Market narrative auditsEos's $87 Million Advance Doesn't Prove Full ProductionThe DOE advance reimburses prior eligible spending. Eos says its second battery line is still ramping toward designed capacity. EOSE · OptimistFi Research Desk ·
Market narrative auditsCan Copart's ACV Deal Reverse Its Profit Decline?Copart agreed to buy ACV for $1.9 billion as quarterly profit fell. Management expects no earnings-per-share boost in the first full year of ownership. CPRT · OptimistFi Research Desk ·

